Evidence map›Paper›PMID 35889459›Full record

ArticleMolecules (Basel, Switzerland)2022

Improvement in Solubility-Permeability Interplay of Psoralens from

Rúbia Darc Machado, Júlio C G Silva, Luís A D Silva, Gerlon de A R Oliveira, Luciano M Lião, Eliana M Lima, Mariana C de Morais, Edemilson C da Conceição, Kênnia R Rezende

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rúbia Darc MachadoLaboratório de Biofarmácia e Farmacocinética (BioPk), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0002-1811-8408
Júlio C G SilvaLaboratório de Biofarmácia e Farmacocinética (BioPk), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.
Luís A D SilvaLaboratório de Nanotecnologia Farmacêutica e Sistemas de Liberação de Fármacos (FarmaTec), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0001-5328-237X
Gerlon de A R OliveiraLaboratório de Ressonância Magnética Nuclear (LabRMN), Instituto de Química, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0002-7936-5429
Luciano M LiãoLaboratório de Ressonância Magnética Nuclear (LabRMN), Instituto de Química, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0001-9985-2980
Eliana M LimaLaboratório de Nanotecnologia Farmacêutica e Sistemas de Liberação de Fármacos (FarmaTec), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0003-1231-5803
Mariana C de MoraisLaboratório de PD&I de Bioprodutos, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0003-3497-4885
Edemilson C da ConceiçãoLaboratório de PD&I de Bioprodutos, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.
Kênnia R RezendeLaboratório de Biofarmácia e Farmacocinética (BioPk), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, GO, Brazil.ORCID 0000-0002-3813-8545
Universidade Federal de Goiás · BR

Funding

National Council for Scientific and Technological Development 407985/2013-1
6 · The paper itself

Abstract

Psoralen (PSO) and 5-methoxypsoralen (5-MOP) are widely used drugs in oral photochemotherapy against vitiligo and major bioactive components of root bark extract of Brosimum gaudichaudii Trécul (EBGT), previously standardized by LC-MS. However, the exceptionally low water solubility of these psoralens can cause incomplete and variable bioavailability limiting their applications and patient adherence to treatment. Therefore, the purpose of this work was to investigate the effects of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex on the solubility and jejunal permeability of PSO and 5-MOP from EBGT. Characterization of inclusion complexes were evaluated by current methods in nuclear magnetic resonance studies on aqueous solution, Fourier transform infrared spectroscopy, thermal analysis, and scanning electron microscopy in solid state. Ex vivo rat jejunal permeability was also investigated and compared for both pure psoralens and plant extract formulation over a wide HP-β-CD concentration range (2.5 to 70 mM). Phase solubility studies of the PSO- and 5-MOP-HP-β-CD inclusion complex showed 1:1 inclusion complex formation with small stability constants (Kc < 500 M−1). PSO and 5-MOP permeability rate decreased after adding HP-β-CD by 6- and 4-fold for pure standards and EBGT markers, respectively. Nevertheless, the complexation with HP-β-CD significantly improved solubility of PSO (until 10-fold) and 5-MOP (until 31-fold). As a result, the permeability drop could be overcome by solubility augmentation, implying that the HP-β-CD inclusion complexes with PSO, 5-MOP, or EBGT can be a valuable tool for designing and developing novel oral drug product formulation containing these psoralens for the treatment of vitiligo.

Indexed as

beta-CyclodextrinsFurocoumarinsMoraceaeVitiligo2-Hydroxypropyl-beta-cyclodextrinAnimalsCalorimetry, Differential ScanningPermeabilityPlant ExtractsRatsSolubilitySpectroscopy, Fourier Transform InfraredX-Ray Diffraction2-Hydroxypropyl-beta-cyclodextrinbeta-CyclodextrinsFurocoumarinsPlant Extractscyclodextrinex vivo permeabilityfuranocoumarinshost–guest interactionHP-β-CDinclusion complexesintestinal absorptionin vitro studiesphysical–chemical characterizationsolubilization

Identifiers

PMID35889459
PMCPMC9322082
OpenAlexW4285799203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.